We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genetic Studies Designed to Diagnose and Treat Complex Diseases

By Biotechdaily staff writers
Posted on 09 May 2007
A genome-wide human single nucleotide polymorphisms (SNP) array 5.0 has been chosen to genotype more than 17,000 individuals.

The German National Genome Research Network (NGFN, Bonn, Germany) has selected Affymetrix (Santa Clara, CA, USA) technology to help researchers better understand the underlying causes and develop more effective treatments for 25 complex diseases, including Alzheimer's, epilepsy, heart diseases, malaria, and Parkinson's. More...
The NGFN will use the new SNP array 6.0 when it becomes available later this year.

With this large-scale project, we hope to encourage the launch of further projects of this kind, said Prof. Stefan Schreiber of the University of Kiel (Germany). Our aim is to discover how similar diseases are linked in order to identify genes related to multiple diseases. In near time, the global community will have the chance of a joint analysis across countries using multiple association samples. The ability to analyze large sample cohorts such as these with cutting-edge technologies is crucial to understanding complex genetics.

The latest NGFN project builds on the success of the first project, which focused on developing a control cohort database that would be free and available to the public. The database is enabling researchers from both academia and the pharmaceutical industry to reduce the number of required control samples and increase the genetic power of their current studies by adding age- and sex-matched controls from similar ethnic backgrounds as their cases. As a result of this project and others around the world, the Affymetrix Control Program is now the world's largest population genetics resource, containing genotype data from more than 12,000 samples.

The project is part of one of the world's largest genetic research efforts. The NGFN consists of a team of scientists from more than 10 research institutions around the country who are committed to standardizing the set of controls, protocols, and analysis tools for whole-genome association studies. Results of the studies will flow into a database accessible to both researchers from academia and the pharmaceutical industry.

The Affymetrix SNP array 5.0 was developed to help researchers better identify and understand the genetic variations associated with complex diseases, such as autism, bipolar disease, cancer, diabetes, and heart disease. The SNP array 5.0 features from the original Affymetrix two-chip 500K array set, as well as 420,000 additional probes that can measure other genetic differences, such as copy number variation. The SNP array 5.0 gives researchers a significant increase in information above the original 500K array set for the same price, while reducing the array processing time. The NGFN will also have access to the next-generation SNP array 6.0, which is expected to be available later this year.


Related Links:
Affymetrix
University of Kiel

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.